IXHLIncannex Healthcare Inc


$ 2.39 $ 0.06 (2.51 %)    

Wednesday, 08-May-2024 15:57:37 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 2.45
$ 2.35
$ 0.00 x 0
$ 0.00 x 0
$ 2.33 - $ 2.39
$ 1.96 - $ 12.68
34,308
na
na
$ 0.19
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-experts-weigh-in-on-incannexs-cannquit-o-with-feedback-on-cbd-as-treatment-for-opioid-use-disorder

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of ...

 psychedelic-assisted-therapy-advancements-create-a-new-horizon-for-mental-health-in-colorado

Psilocybin-assisted therapy shows promise in treating GAD. Denver trains first responders in psychedelic crisis intervention. H...

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 incannex-healthcare-tapped-treasurer-and-controller-joseph-swan-to-additional-role-of-cfo-effective-february-29-after-madhukar-bhalla-decided-to-retire

Madhukar Bhalla, Chief Financial Officer and Secretary of Incannex Healthcare Inc. (the “Company”), recently notified the Compa...

 why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

 whats-going-on-with-incannex-stock

Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint o...

Core News & Articles

BYND: 105% | Beyond Meat shares are trading higher after the company reported mixed Q4 financial results. FLYW: 31% | Flywire ...

 incannex-announces-topline-results-from-phase-2-psi-gad1-clinical-trial-of-psilocybin-in-generalised-anxiety-disorder

Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION